Single dose of CBD reduces alcohol craving and brain reactivity in alcoholics

A recent study of individuals with alcohol use disorder found that a single 800 mg dose of cannabidiol reduced alcohol cravings and dampened activity in a key brain region involved in addiction. Specifically, cannabidiol lowered activation in the nucleus accumbens in response to alcohol cues, such as the sight or handling of a participant’s preferred alcoholic drink. The findings were published in Molecular Psychiatry.

Cannabidiol (CBD) is a non-intoxicating compound found in the cannabis plant. Unlike tetrahydrocannabinol (THC)—the primary psychoactive ingredient in cannabis—CBD does not produce a high and is generally considered safe. It interacts with the body’s endocannabinoid system, which helps regulate mood, pain, sleep, and immune responses. CBD has attracted growing interest for its potential therapeutic properties, including reducing anxiety, inflammation, and seizures.

In fact, the U.S. Food and Drug Administration has approved a CBD-based medication called Epidiolex for the treatment of rare forms of epilepsy. CBD is widely available in the form of oils, capsules, edibles, and topical creams, although scientific evidence remains limited for many of its popular uses.

Study author Sina Zimmermann and her colleagues tested whether CBD could reduce alcohol craving triggered by environmental cues—a phenomenon known as cue-induced craving—and whether it could reduce activation in the nucleus accumbens, a brain region involved in reward and motivation. In individuals with alcohol use disorder, exposure to alcohol-related cues such as sight, smell, or contextual reminders of drinking often triggers elevated nucleus accumbens activity and increased craving. This heightened brain response can drive compulsive use and increase the risk of relapse.

The researchers recruited 28 adults with mild to severe alcohol use disorder who were not currently seeking treatment. Their average age was 36. On average, participants met 5.4 of the criteria for alcohol use disorder, reported drinking about 46 grams of alcohol per day, and had 36% heavy drinking days over the past 90 days. Participants were randomly assigned to receive either 800 mg of CBD (delivered as four 200 mg capsules) or an identical-looking placebo. All participants were instructed to abstain from alcohol for at least 24 hours before the study session.

Three hours after taking the assigned capsules—timed to coincide with peak CBD absorption—participants underwent a series of tasks. First, they completed the Trier Social Stress Test, which involved delivering a speech and performing mental arithmetic in front of evaluators. They were then shown and allowed to handle their favorite alcoholic drinks in a controlled bar-laboratory setting. This combination of stress and alcohol cues was designed to provoke craving.

Next, participants underwent functional magnetic resonance imaging (fMRI), where they were again shown alcohol-related cues while brain activity was recorded. Throughout the session, participants reported their craving levels using the Alcohol Urge Questionnaire and a visual analog scale.

The results showed that participants who received CBD reported significantly lower craving levels after the stress and cue exposure compared to those who received a placebo. During the fMRI session, they also showed reduced craving and significantly lower activity in the left and right nucleus accumbens when exposed to alcohol-related images. These effects were specific to alcohol cues; CBD did not significantly affect brain activity during neutral cue blocks.

Importantly, participants with higher concentrations of CBD in their blood had lower self-reported craving and lower nucleus accumbens activation, indicating a dose-response relationship. The researchers found no evidence that sex, age, body mass index, or smoking status predicted CBD blood levels, suggesting individual variability in absorption or metabolism.

“CBD’s capacity to reduce stress- and cue-induced alcohol craving and to normalize NAc [nucleus accumbens] activation – a region critical to the pathophysiology of AUD [alcohol use disorder] – contribute to understanding the neurobiological basis of its clinical effects and support its potential as a treatment option for AUD,” the study authors concluded.

The study provides preliminary clinical evidence that CBD may reduce alcohol craving and blunt the brain’s reactivity to alcohol cues in individuals with alcohol use disorder. However, it also has several limitations. The sample size was small, and the study tested only a single acute dose. It remains unknown whether these effects would persist or grow stronger with repeated use, or how they might apply to individuals actively seeking treatment for alcohol use.

Additionally, because the fMRI scan occurred after both the stress and cue exposure, it’s difficult to disentangle whether CBD’s effects were due to reduced cue reactivity, reduced stress response, or both. Still, the procedures were consistent across groups, and the observed differences suggest that CBD could be influencing core processes involved in alcohol craving.

The paper “Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial” was authored by Sina Zimmermann, Anton Teetzmann, Joscha Baeßler, Lena Schreckenberger, Judith Zaiser, Marlen Pfisterer, Manuel Stenger, and Patrick Bach.